scholarly journals Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma

2012 ◽  
Vol 19 (6) ◽  
pp. 779-784 ◽  
Author(s):  
M Bullock ◽  
C O'Neill ◽  
A Chou ◽  
A Clarkson ◽  
T Dodds ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Gold Standard ◽  
Sanger Sequencing ◽  
Sampling Error ◽  
Molecular Data ◽  
Papillary Thyroid ◽  
Formalin Fixed Paraffin ◽  
Thyroid Neoplasia ◽  
Formalin Fixed Paraffin Embedded

Identification of BRAFV600E in thyroid neoplasia may be useful because it is specific for malignancy, connotes a worse prognosis, and is the target of novel therapies currently under investigation. Sanger sequencing is the ‘gold standard’ for mutation detection but is subject to sampling error and requires resources beyond many diagnostic pathology laboratories. In this study, we compared immunohistochemistry (IHC) using a BRAFV600E mutation-specific MAB to Sanger sequencing on DNA from formalin-fixed paraffin-embedded tissue, in a well-characterized cohort of 101 papillary thyroid carcinoma (PTC) patients. For all cases, an IHC result was available; however, five cases failed Sanger sequencing. Of the 96 cases with molecular data, 68 (71%) were BRAFV600E positive by IHC and 59 (61%) were BRAFV600E positive by sequencing. Eleven cases were discordant. One case was negative by IHC and initially positive by sequencing. Repeat sequencing of that sample and sequencing of a macrodissected sample were negative for BRAFV600E. Of ten cases positive by IHC but negative by sequencing on whole sections, repeat sequencing on macrodissected tissue confirmed the IHC result in seven cases (suggesting that these were false negatives of sequencing on whole sections). In three cases, repeat sequencing on recut tissue remained negative (including using massive parallel sequencing), but these cases demonstrated relatively low neoplastic cellularity. We conclude that IHC for BRAFV600E is more sensitive and specific than Sanger sequencing in the routine diagnostic setting and may represent the new gold standard for detection of BRAFV600E mutation in PTC.

scholarly journals Different stability of miRNAs and endogenous control genes in archival specimens of papillary thyroid carcinoma

2020 ◽  
Vol 26 (1) ◽  
Author(s):  
Daina Pamedytyte ◽  
Enrika Leipute ◽  
Birute Zilaitiene ◽  
Valdas Sarauskas ◽  
Dalia Dauksiene ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Mirna Expression ◽  
Endogenous Control ◽  
Papillary Thyroid ◽  
Tissue Samples ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
The Stability ◽  
The Impact

Abstract Background The most popular miRNA quantitation technique is RQ-PCR with relative gene expression method that requires an endogenous control (EC) gene for data normalization. However, there are insufficient data and selection criteria on the most suitable ECs for miRNA expression studies in many cancer types including papillary thyroid carcinoma (PTC). Therefore, in this study we evaluated the impact of chosen EC and archival formalin-fixed, paraffin-embedded (FFPE) PTC tissue age on estimated target miRNA expression. Methods RQ-PCR was used to determine expression levels of five miRNAs (miR-146b, miR-222, miR-21, miR-221 and miR-181b) and three different endogenous controls (RNU48, let-7a, miR-16), which were used to normalize the data. In total, 400 FFPE PTC tissues were analyzed that have been stored from 1 to 15 years. Results The stability of commonly used ECs RNU48 and let-7a significantly differs from the stability of target miRNA in archival FFPE PTC tissues. Moreover, these differences have a great impact on miRNA expression results when FFPE tissue samples have been stored for a different period of time. Conclusions It is important to select an ECs not only stable in the tissue of interest but also with similar stability to target miRNA, especially when working with samples of different age.

scholarly journals Papillary Thyroid Carcinoma Tissue miR-146b, -21, -221, -222, -181b Expression in Relation with Clinicopathological Features

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 418
Author(s):  
Aistė Kondrotienė ◽  
Albertas Daukša ◽  
Daina Pamedytytė ◽  
Mintautė Kazokaitė ◽  
Aurelija Žvirblienė ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Univariate Analysis ◽  
High Expression ◽  
Clinicopathological Parameters ◽  
Papillary Thyroid ◽  
Tissue Samples ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Node Metastases

We analyzed miR-146b, miR-21, miR-221, miR-21, and miR-181b in formalin fixed paraffin-embedded papillary thyroid carcinoma (PTC) tissue samples of 312 individuals and evaluated their expression relationship with clinicopathological parameters. A higher expression of miR-21 was related to unifocal lesions (p < 0.011) and autoimmune thyroiditis (0.007). miR-221, miR-222 expression was higher in the PTC tissue samples with extrathyroidal extension (p = 0.049, 0.003, respectively). In a group of PTC patients with pT1a and pT1b sized tumors, the expression of miR-146b, miR-21, miR-221, and miR-222 in PTC tissue samples was lower than in patients with pT2, pT3, and pT4 (p = 0.032; 0.0044; 0.003; 0.001; 0.001, respectively). Patients with lymph node metastases had higher expression of miR-21, -221, -222, and -181b (p < 0.05). A high expression of miR-146b, miR-21, miR-221 panel was associated with decreased overall survival (OS) (Log rank p = 0.019). Univariate analysis revealed that presence of metastatic lymph nodes and high expression of miR-146b, miR-21, and miR-221 panels were associated with increased hazard of shorter OS. After multivariate analysis, only sex (male) and age (≥55 years) emerged as independent prognostic factors associated with shorter OS (HR 0.28 (95% CI 0.09–0.86) and HR 0.05 (95% CI 0.01–0.22), respectively). In conclusion, 5 analyzed miRs expression have significant relations to clinicopathologic parameters so further investigations of these molecules are expedient while searching for prognostic PTC biomarkers.

scholarly journals Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma

2017 ◽  
Vol 24 (2) ◽  
pp. 107-117 ◽  
Author(s):  
Luca Morandi ◽  
Alberto Righi ◽  
Francesca Maletta ◽  
Paola Rucci ◽  
Fabio Pagni ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Cox Regression ◽  
Gene Mutations ◽  
Molecular Data ◽  
Genetic Alterations ◽  
Papillary Thyroid ◽  
Primary Tumors ◽  
Mutational Pattern ◽  
Prognostic Stratification

Hobnail variant of papillary thyroid carcinoma (HPTC) represents a recently described, aggressive and rare group of thyroid tumors with poorly understood pathogenesis. Molecular data about this group of cancers are few, and a more detailed molecular characterization of these tumors is needed. The main objective of the study is to define a comprehensive molecular typing of HPTC. Eighteen patients affected by HPTC, including eighteen primary tumors and four lymph node metastases, were screened forNRAS,KRAS,HRAS,BRAF,TP53,PIK3CA,hTERT,PTEN,CDKN2A,EGFR,AKT1,CTNNB1andNOTCH1gene mutations. Sequencing is conducted on the MiSEQ system, and molecular data are compared with clinical-pathologic data and follow-up. The patients include 14 women and 4 men. Ages range from 23 to 87 years. All 18 primary tumors of HPTC showed ≥30% hobnail features.BRAFandTP53mutations are by far the most common genetic alterations in primary HPTC (72.2% and 55.6%, respectively), followed byhTERT(44.4%),PIK3CA(27.8%),CTNNB1(16.7%),EGFR(11.1%),AKT1(5.5%) andNOTCH1(5.5%). The mutational pattern in primary tumors and metastasis was usually maintained. Univariate Cox regression analyses with bootstrap procedure indicated a significantly increased mortality risk in patients harboringBRAFmutation andBRAFmutation associated withTP53and/orPIK3CAmutations. The detection of these multiple mutations appears to allow the identification of a subset of more aggressive tumors within the group and to bear information that should be useful for prognostic stratification of these patients including the planning of adjuvant therapy.

scholarly journals Encapsulated Follicular variant of papillary thyroid carcinoma: Is histopathology a gold standard?

2013 ◽  
Vol 2 (4) ◽  
pp. 231
Author(s):  
ChagantiPadmavathi Devi ◽  
KarriMaruti Devi ◽  
Suneeta Kotakonda ◽  
MPartha Akarsh
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Gold Standard ◽  
Papillary Thyroid ◽  
Follicular Variant
Sign in / Sign up

Export Citation Format

Share Document